PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Veterinary Drugs”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1984

[Drugs in veterinary medicine. The role of the veterinary drug industry].

Veterinary medicines constitute an unescapable element in the scheme of animal health and welfare. Nowadays, they are used more and more to improve health and productivity in farm animals. When a veterinary medicine is prescribed it must not only be effective but must also be safe for both animals and humans. Due to ever changing regulations and constant improvements in residue detection techniques it is necessary to conduct new investigations with existing products. It therefore costs a great deal of time and money to introduce, and maintain, a product in the market. In future, therefore, fewer medicines with more limited indications will be introduced and these will be to combat important production disorders in the more significant species only. In view of the above, research and production will be restricted to large, international, concerns. Due to our well structured agricultural industry and the existence of well organized and equipped veterinary research institutions, and practitioners, Holland is able to play an important role in the development of veterinary medicines. Close co-operation between all involved parties coupled with an efficient registration procedure is not ony of benefit to the veterinary pharmaceutical industry but also for international recognition of our national animal husbandry industry, ancillary industries and veterinary and other consultants. In this scheme of things the accent is not upon qualifications but upon the skills of veterinarians - wherever placed - who are involved in the administration of veterinary medicines.

Animals↗
PubMed1990

[Veterinary drugs and good veterinary practice].

The following definition of 'Good Veterinary Practice' in relation to pharmacotherapy is presented: 'The selective use (in accordance with directions for users) of veterinary drugs registered by the authorities in those indications in which they are permitted when the diagnosis has been established and in which the problem of residues in foods of animal origin on using these agents has been taken into account'. The following recommendations are made with reference to 'Good Principles of Veterinary Practice': (1) Current training and supplementary training in the fields of pharmacy and pharmacotherapy should be adjusted in the light of recent developments in society. (2) The development of simple, rapid and reliable tests for the detection of pathogenic agents and residues of veterinary drugs should stimulated. (3) The development of conveniently arranged and standardised data sheets in generally comprehensible terms should receive sufficient attention. (4) Quality control, particularly of generic products, deserves adequate attention. (5) The institution of a Side-Effects of Veterinary Drugs Office, in which the authorities, manufacturers and other parties concerned co-operate closely, is eminently desirable. (6) The establishment of a Veterinary Drugs Committee in which all interested parties are represented, is of the utmost importance within the framework of recommendations on policy to the authorities.

Animals↗
PubMed1987

[Veterinary drugs, the veterinarian and the Veterinary Drug Act].

A number of features of the Veterinary Medicinal Products Act, which are of importance to veterinarians, are reviewed. These features result in a number of consequences connected with obtaining and handling veterinary drugs. These consequences are discussed.

Animals↗
PubMed1987

[The Veterinary Drug Act and rational pharmacotherapy. Various marginal notes on the registration and channeling of veterinary drugs].

A short introductory note is followed by a more detailed discussion of a number of aspects of the administration of the Veterinary Medicinal Products Act. Among other things, attention is paid to the following subjects: the Registration of Veterinary Drugs Committee (RVDC) and its working parties (no participation of specialists from the Faculty of Veterinary Medicine, no varied membership of the Veterinary Drugs Committee), the veterinary use of drugs registered for human use (supplementary registration), the position of particular species of animals (supplementary registration), the records (no environmental requirements, absence of clear directions for the toxicological evaluation of veterinary-drug metabolites, risks of the number of veterinary drugs available being reduced) and the criteria of directing veterinary drugs into specific channels ('veterinarians only' system, role of pharmaceutical chemists). It would also appear to be advisable that the Committee specify within a short time which antibiotics are not eligible for veterinary use. This also holds good for substances such as mutagenic and carcinogenic compounds showing doubtful toxicological characteristics.

Animals↗
PubMed1990

[Toxicological considerations in the evaluation of veterinary drugs].

Interactions between veterinary pharmacotherapy, toxicology of residues, prevention of residues of veterinary drugs and the evaluation of veterinary drug files are discussed on the basis of a number of examples. Sulphadimidine is used to treat atrophic rhinitis in medicated feeds which do not benefit the animal but are the cause of persistent sulphonamide residues in feed mills and husbandry. Carbadox is a potentially effective prophylactic feed additive for the prevention of swine dysentery, but is mostly used in high dosages which are almost toxic for the animals, and used during unnecessary prolonged periods. It is also prescribed as a therapeutic agent in which case a symptom of poisoning, dry faeces, is mistaken for a sign of recovery. Carbadox and/or its metabolites are carcinogenic and its use should be restricted to a bare minimum. Furazolidone is an example of an effective veterinary drug, the use of which should be limited by the fact that detoxification mechanisms of the animals, may result in the appearance of reactive metabolites which are available in the gastro-intestinal tract of the consumer. The central issue in a 'minimal residue' policy regarding the use of veterinary drugs should be the selection of effective drugs. Such a selection could result in a significant reduction of the incidence of veterinary drug residues. Second to this issue is the question of the extent to which residue toxicology should modulate the use of veterinary drugs.

Animals↗
PubMed1987

[The Veterinary Drug Act, the Veterinary Practice Act and the cattle farmer].

The concept of 'local practising' will disappear in the new legislation. This will render veterinary medicine by mail order possible. From the point of view of the quality of the ultimate product, this development should be strongly rejected. The section will benefit by an expert and payable herd management programme which has as its object a justified use of drugs and a 'clean ultimate product' (healthy animals).

Animal Husbandry↗
PubMed1984

[Records and the use of veterinary drugs].

The new Veterinary Drugs Act is in process of development. The final form which this law will take on will probably be clearer by the time of the 1983 annual congress. It can be expected that only registered drugs will then be permissible for use in treatment. A drug is registered when records are provided and found to be adequate, which show that the drug is effective and does not have any injurious side-effects or results in the appearance of residues after normal use. Drawing up a record of this type requires thorough investigation of the drug, in which experimental studies in animals play an important role. The problem of residues does not enter into the matter in the case of veterinary drugs used in companion animals, though beyond this the registration system will not differ markedly from that of other agents. This means that drugs used in human medicine as such are not permissible for use in companion animals. As several of the required data from the records of these drugs will then be available, composing a complete record will not cause any insurmountable problems. The situation is more complicated in the case of homeopathic and allied therapeutic agents.

Animals↗
PubMed1996

Dietary intake estimates as a means to the harmonization of maximum residue levels for veterinary drugs. II. Proposed application to the Free Trade Agreement between the United States and Canada.

The Free Trade Agreement between the United States and Canada (FTA) went into effect January 1, 1989. To implement certain provisions of the agreement on technical regulations and standards, the United States Food and Drug Administration's Center for Veterinary Medicine, Health and Welfare Canada's Bureau of Veterinary Drugs, and Agriculture Canada established the Working Group on Veterinary Drug Tolerances. The progress of the working group and its continuing efforts to harmonize tolerances for approximately 15 veterinary drugs are discussed. This paper proposes use of the toxicologically determined acceptable daily intake (ADI) for the drug as the safety standard for reaching conclusions on the acceptability of residues in meat for human consumption. Specifically, the "equivalence" of different MRLs for the same veterinary drug would be determined by considering whether they are likely to result in dietary residues that exceed the other country's ADI for the drug. Estimates are made for the veterinary drugs lasalocid, fenbendazole, morantel tartrate, halofuginone, and tilmicosin. Based on these estimates, the U.S. and Canadian MRLs for each drug would be considered equivalent for trade purposes.

Animals↗
PubMed1986

Codex committee on veterinary drug residues.

There has been widespread international concern over residues of veterinary drugs in food. However, until recently, there was little international cooperation in trying to find solutions to the problem. Many nations have taken steps to control the increased use of veterinary drugs, but the rules governing their use vary widely from country to country. Sharing of scientific expertise and other resources between countries would markedly improve this situation. With the need for international cooperation mounting, concerned drug regulators from 20 countries met in 1982 and again in 1984 to discuss international use of veterinary drugs. The group repeatedly called for a Codex committee on veterinary drug residues. At its 1983 meeting in Rome the Codex Alimentarius Commission convened an Expert Consultation to consider the need for a new committee. That international group of experts strongly agreed that a standing committee under the sponsorship of the commission should be established. In July of 1985, the commission unanimously voted to establish a new Committee on Residues of Veterinary Drugs in Food. The United States was chosen as host country. The committee will work closely with several existing Codex committees, but it has a clear mandate of its own. Its responsibilities will include establishing a list of priority drugs for review, recommending maximum residue levels, developing codes of practice, and reviewing analytical methods used to control veterinary drug residues. This fall, a new Codex committee has met for the first time--the Codex Committee on Residues of Veterinary Drugs in Food.(ABSTRACT TRUNCATED AT 250 WORDS)

Agriculture↗
PubMed1986

[Veterinary Drug Act].

The Dutch Veterinary Drug Act is reviewed and the consequences of a number of aspects of this act are discussed.

Animals↗
PubMed2001

Transference of dietary veterinary drugs into eggs.

Twelve veterinary drugs, bacitracin (BC), chloramphenicol (CAP), chlortetracycline (CTC), oxytetracycline (OTC), tylosin (TS), amprolium (APL), furazolidone (FZD), nicarbazine (NCZ), ormetoprium (OMP), sulfadimidine (SDD), sulfadimethoxine (SDM) and sulfamonomethoxine (SMM) were fed to laying hens for 14 days, each at a dietary concentration of 500 mg/kg. The concentrations of the drugs in the eggs from these birds were determined at 2-day intervals for 14 days after the start of feeding. The relationship between the concentrations of the drugs (mg/kg) in the eggs and the number of days after the start of feeding was analysed by regression and covariance analyses. The concentrations of the drugs in the eggs became constant after 4 days for OTC, TS, FZD and all the sulfonamides, and after 6 days for CAP, APL, NCZ and OMP. No BC or CTC was detected in the eggs. The transfer rates of the 10 drugs (excluding BC and CTC) from the feed to eggs varied from 0.005% for TS up to 1.540% for SDD.

Albumins↗
PubMed2006

Role of ABC transporters in veterinary drug research and parasite resistance.

A considerable body of research has been carried out in order to throw light on the pharmacological and toxicological impact of ATP-binding cassette (ABC) drug efflux transporters such as P-glycoprotein and Breast Cancer Resistance Protein (BCRP/ABCG2/MXR). Most studies focus on their role in rendering cancer cells resistant to anticancer drugs. Drug transporters are expressed in many tissues and they are strongly involved in the oral bioavailability, and the hepatobiliary, direct intestinal and renal excretion of many drugs. In veterinary therapy, some anti parasitic drugs and/or their metabolites, such as ivermectin, moxidectin, albendazole sulfoxide, which are widely used, have been shown to be actively transported by efflux pumps. This interaction plays an important role in drug disposition since its inhibition has been shown to increase the drug bioavailability in some domestic species. Moreover, some authors have reported that parasite resistance to anthelmintic drugs may be mediated by parasite P-glycoprotein efflux. In addition, the importance of milk residues for human nutrition has aroused increasing concern about the inadvertent transfer of drugs and other substances into mammary milk of domestic animals, potentially posing a health risk to consumers. Recently, the important role of BCRP in the secretion of its substrates in milk has been demonstrated.

ATP-Binding Cassette Transporters↗
PubMed1990

[The use of pharmacological criteria in the toxicological evaluation of veterinary drugs].

The toxicological evaluation of residues of veterinary drugs in foods of animal origin, which is done within the framework of the Netherlands Veterinary Drugs Act, is based on an EEC guide line in which, in addition to the clinical and analytical criteria, the requirements regarding the pharmacological and toxicological evaluation are laid down. In principle, this evaluation is based on classical toxicological criteria. As veterinary drugs have a specific pharmacological action, it is essential that these pharmacological effects should be in included in the toxicological evaluation in view of an adequate protection of public health. The selected starting point is that a pharmacological effect desired in a target animal is regarded as an undesirable effect in consumers. In this presentation, two examples are referred to, viz. the bèta agonist clenbuterol and the bèta-blocking agent carazolol; the approach is compared with a 'classical' toxicological evaluation. This shows that the acceptable daily intake in human individuals (ADI), based on pharmacological criteria is lower by a factor of approximately 50 than is the ADI on the basis of 'classical' toxicological criteria. This clearly illustrates the value of this approach in protecting the health of consumers.

Adrenergic beta-Antagonists↗